Which has preferable earnings and valuation, LQDA or NVCR?

Liquidia has higher earnings, but lower revenue than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Liquidia $158.32M 43.30 -$68.92M $0.14 550.57 NovoCure $655.35M 2.82 -$136.23M -$1.53 N/A

Is LQDA or NVCR more profitable?

Liquidia has a net margin of 7.74% compared to NovoCure's net margin of -25.66%. Liquidia's return on equity of 46.82% beat NovoCure's return on equity. Company Net Margins Return on Equity Return on Assets Liquidia 7.74% 46.82% 7.06% NovoCure -25.66% -50.82% -16.48%

Does the media prefer LQDA or NVCR?

In the previous week, Liquidia had 28 more articles in the media than NovoCure. MarketBeat recorded 33 mentions for Liquidia and 5 mentions for NovoCure. Liquidia's average media sentiment score of 0.28 beat NovoCure's score of -0.01 indicating that Liquidia is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Liquidia 13 Very Positive mention(s) 3 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral NovoCure 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer NVCR or STVN?

NovoCure presently has a consensus target price of $23.60, indicating a potential upside of 48.06%. Given NovoCure's higher possible upside, equities research analysts plainly believe NovoCure is more favorable than Stevanato Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NovoCure 2 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.00 Stevanato Group 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 3.00

Which has higher valuation and earnings, NVCR or STVN?

Stevanato Group has higher revenue and earnings than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than Stevanato Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NovoCure $655.35M 2.82 -$136.23M -$1.53 N/A Stevanato Group €1.34B 4.34 €158.21M €0.59 32.61

Does the media favor NVCR or STVN?

In the previous week, NovoCure had 1 more articles in the media than Stevanato Group. MarketBeat recorded 5 mentions for NovoCure and 4 mentions for Stevanato Group. Stevanato Group's average media sentiment score of 1.27 beat NovoCure's score of -0.01 indicating that Stevanato Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NovoCure 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Stevanato Group 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is NVCR or BLCO more profitable?

Bausch + Lomb has a net margin of -4.21% compared to NovoCure's net margin of -25.66%. Bausch + Lomb's return on equity of 3.60% beat NovoCure's return on equity. Company Net Margins Return on Equity Return on Assets NovoCure -25.66% -50.82% -16.48% Bausch + Lomb -4.21% 3.60% 1.69%

Does the media refer more to NVCR or BLCO?

In the previous week, NovoCure had 3 more articles in the media than Bausch + Lomb. MarketBeat recorded 5 mentions for NovoCure and 2 mentions for Bausch + Lomb. Bausch + Lomb's average media sentiment score of 0.87 beat NovoCure's score of -0.01 indicating that Bausch + Lomb is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NovoCure 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Bausch + Lomb 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, LIVN or NVCR?

NovoCure has lower revenue, but higher earnings than LivaNova. NovoCure is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LivaNova $1.39B 3.13 -$242.47M $1.95 40.62 NovoCure $655.35M 2.82 -$136.23M -$1.53 N/A

Is LIVN or NVCR more profitable?

LivaNova has a net margin of 7.48% compared to NovoCure's net margin of -25.66%. LivaNova's return on equity of 16.48% beat NovoCure's return on equity. Company Net Margins Return on Equity Return on Assets LivaNova 7.48% 16.48% 7.59% NovoCure -25.66% -50.82% -16.48%

Does the media prefer LIVN or NVCR?

In the previous week, NovoCure had 4 more articles in the media than LivaNova. MarketBeat recorded 5 mentions for NovoCure and 1 mentions for LivaNova. LivaNova's average media sentiment score of 0.72 beat NovoCure's score of -0.01 indicating that LivaNova is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LivaNova 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NovoCure 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor NVCR or MMED?

In the previous week, MiniMed Group had 9 more articles in the media than NovoCure. MarketBeat recorded 14 mentions for MiniMed Group and 5 mentions for NovoCure. MiniMed Group's average media sentiment score of 0.09 beat NovoCure's score of -0.01 indicating that MiniMed Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NovoCure 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral MiniMed Group 1 Very Positive mention(s) 0 Positive mention(s) 13 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

NovoCure (NVCR) Competitors

$15.94 +0.02 (+0.13%)

Closing price 07/20/2026 04:00 PM Eastern

Extended Trading

$15.87 -0.07 (-0.46%)

As of 07/20/2026 07:41 PM Eastern

Compare

NVCR vs. LQDA, STVN, BLCO, LIVN, and MMED

Should you buy NovoCure stock or one of its competitors? MarketBeat compares NovoCure with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with NovoCure include Liquidia (LQDA), Stevanato Group (STVN), Bausch + Lomb (BLCO), LivaNova (LIVN), and MiniMed Group (MMED). These companies are all part of the "medical equipment" industry.

How does NovoCure compare to Liquidia?

Liquidia (NASDAQ:LQDA) and NovoCure (NASDAQ:NVCR) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, media sentiment, risk and dividends.

Liquidia presently has a consensus price target of $68.88, suggesting a potential downside of 10.64%. NovoCure has a consensus price target of $23.60, suggesting a potential upside of 48.06%. Given NovoCure's higher probable upside, analysts plainly believe NovoCure is more favorable than Liquidia.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Liquidia	2 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	3 Strong Buy rating(s)	2.82
NovoCure	2 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Liquidia had 28 more articles in the media than NovoCure. MarketBeat recorded 33 mentions for Liquidia and 5 mentions for NovoCure. Liquidia's average media sentiment score of 0.28 beat NovoCure's score of -0.01 indicating that Liquidia is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Liquidia	13 Very Positive mention(s)	3 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
NovoCure	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

64.5% of Liquidia shares are held by institutional investors. Comparatively, 84.6% of NovoCure shares are held by institutional investors. 25.6% of Liquidia shares are held by insiders. Comparatively, 5.5% of NovoCure shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Liquidia has a beta of 0.55, suggesting that its share price is 45% less volatile than the broader market. Comparatively, NovoCure has a beta of 0.94, suggesting that its share price is 6% less volatile than the broader market.

Liquidia has higher earnings, but lower revenue than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Liquidia	$158.32M	43.30	-$68.92M	$0.14	550.57
NovoCure	$655.35M	2.82	-$136.23M	-$1.53	N/A

Liquidia has a net margin of 7.74% compared to NovoCure's net margin of -25.66%. Liquidia's return on equity of 46.82% beat NovoCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Liquidia	7.74%	46.82%	7.06%
NovoCure	-25.66%	-50.82%	-16.48%

Summary

Liquidia beats NovoCure on 13 of the 17 factors compared between the two stocks.

How does NovoCure compare to Stevanato Group?

NovoCure (NASDAQ:NVCR) and Stevanato Group (NYSE:STVN) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, media sentiment, profitability, dividends, analyst recommendations and valuation.

NovoCure has a beta of 0.94, meaning that its share price is 6% less volatile than the broader market. Comparatively, Stevanato Group has a beta of 0.78, meaning that its share price is 22% less volatile than the broader market.

Stevanato Group has a net margin of 11.76% compared to NovoCure's net margin of -25.66%. Stevanato Group's return on equity of 10.27% beat NovoCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NovoCure	-25.66%	-50.82%	-16.48%
Stevanato Group	11.76%	10.27%	6.08%

84.6% of NovoCure shares are owned by institutional investors. 5.5% of NovoCure shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

NovoCure presently has a consensus target price of $23.60, indicating a potential upside of 48.06%. Given NovoCure's higher possible upside, equities research analysts plainly believe NovoCure is more favorable than Stevanato Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NovoCure	2 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
Stevanato Group	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.00

Stevanato Group has higher revenue and earnings than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than Stevanato Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NovoCure	$655.35M	2.82	-$136.23M	-$1.53	N/A
Stevanato Group	€1.34B	4.34	€158.21M	€0.59	32.61

In the previous week, NovoCure had 1 more articles in the media than Stevanato Group. MarketBeat recorded 5 mentions for NovoCure and 4 mentions for Stevanato Group. Stevanato Group's average media sentiment score of 1.27 beat NovoCure's score of -0.01 indicating that Stevanato Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NovoCure	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Stevanato Group	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Stevanato Group beats NovoCure on 11 of the 16 factors compared between the two stocks.

How does NovoCure compare to Bausch + Lomb?

NovoCure (NASDAQ:NVCR) and Bausch + Lomb (NYSE:BLCO) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, earnings, dividends, analyst recommendations and institutional ownership.

NovoCure has a beta of 0.94, suggesting that its share price is 6% less volatile than the broader market. Comparatively, Bausch + Lomb has a beta of 0.56, suggesting that its share price is 44% less volatile than the broader market.

NovoCure has higher earnings, but lower revenue than Bausch + Lomb. Bausch + Lomb is trading at a lower price-to-earnings ratio than NovoCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NovoCure	$655.35M	2.82	-$136.23M	-$1.53	N/A
Bausch + Lomb	$5.10B	1.12	-$360M	-$0.62	N/A

NovoCure presently has a consensus price target of $23.60, suggesting a potential upside of 48.06%. Bausch + Lomb has a consensus price target of $18.00, suggesting a potential upside of 12.70%. Given NovoCure's higher possible upside, research analysts plainly believe NovoCure is more favorable than Bausch + Lomb.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NovoCure	2 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
Bausch + Lomb	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21

84.6% of NovoCure shares are held by institutional investors. Comparatively, 11.1% of Bausch + Lomb shares are held by institutional investors. 5.5% of NovoCure shares are held by company insiders. Comparatively, 1.5% of Bausch + Lomb shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Bausch + Lomb has a net margin of -4.21% compared to NovoCure's net margin of -25.66%. Bausch + Lomb's return on equity of 3.60% beat NovoCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NovoCure	-25.66%	-50.82%	-16.48%
Bausch + Lomb	-4.21%	3.60%	1.69%

In the previous week, NovoCure had 3 more articles in the media than Bausch + Lomb. MarketBeat recorded 5 mentions for NovoCure and 2 mentions for Bausch + Lomb. Bausch + Lomb's average media sentiment score of 0.87 beat NovoCure's score of -0.01 indicating that Bausch + Lomb is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NovoCure	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Bausch + Lomb	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

NovoCure and Bausch + Lomb tied by winning 8 of the 16 factors compared between the two stocks.

How does NovoCure compare to LivaNova?

LivaNova (NASDAQ:LIVN) and NovoCure (NASDAQ:NVCR) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings, profitability and risk.

LivaNova has a beta of 0.86, indicating that its stock price is 14% less volatile than the broader market. Comparatively, NovoCure has a beta of 0.94, indicating that its stock price is 6% less volatile than the broader market.

LivaNova has a net margin of 7.48% compared to NovoCure's net margin of -25.66%. LivaNova's return on equity of 16.48% beat NovoCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LivaNova	7.48%	16.48%	7.59%
NovoCure	-25.66%	-50.82%	-16.48%

97.6% of LivaNova shares are held by institutional investors. Comparatively, 84.6% of NovoCure shares are held by institutional investors. 0.4% of LivaNova shares are held by company insiders. Comparatively, 5.5% of NovoCure shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

LivaNova currently has a consensus target price of $81.38, indicating a potential upside of 2.73%. NovoCure has a consensus target price of $23.60, indicating a potential upside of 48.06%. Given NovoCure's higher probable upside, analysts clearly believe NovoCure is more favorable than LivaNova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LivaNova	0 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.60
NovoCure	2 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, NovoCure had 4 more articles in the media than LivaNova. MarketBeat recorded 5 mentions for NovoCure and 1 mentions for LivaNova. LivaNova's average media sentiment score of 0.72 beat NovoCure's score of -0.01 indicating that LivaNova is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LivaNova	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NovoCure	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

NovoCure has lower revenue, but higher earnings than LivaNova. NovoCure is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LivaNova	$1.39B	3.13	-$242.47M	$1.95	40.62
NovoCure	$655.35M	2.82	-$136.23M	-$1.53	N/A

Summary

LivaNova beats NovoCure on 11 of the 16 factors compared between the two stocks.

How does NovoCure compare to MiniMed Group?

NovoCure (NASDAQ:NVCR) and MiniMed Group (NASDAQ:MMED) are both medical equipment companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, analyst recommendations, valuation, media sentiment and institutional ownership.

NovoCure has higher earnings, but lower revenue than MiniMed Group. MiniMed Group is trading at a lower price-to-earnings ratio than NovoCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NovoCure	$655.35M	2.82	-$136.23M	-$1.53	N/A
MiniMed Group	$3.10B	1.53	-$190.97M	-$0.68	N/A

84.6% of NovoCure shares are owned by institutional investors. Comparatively, 19.7% of MiniMed Group shares are owned by institutional investors. 5.5% of NovoCure shares are owned by company insiders. Comparatively, 2.2% of MiniMed Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

NovoCure currently has a consensus price target of $23.60, indicating a potential upside of 48.06%. MiniMed Group has a consensus price target of $21.33, indicating a potential upside of 26.08%. Given NovoCure's higher possible upside, analysts clearly believe NovoCure is more favorable than MiniMed Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NovoCure	2 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
MiniMed Group	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.73

MiniMed Group has a net margin of 0.00% compared to NovoCure's net margin of -25.66%. MiniMed Group's return on equity of 0.00% beat NovoCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NovoCure	-25.66%	-50.82%	-16.48%
MiniMed Group	N/A	N/A	N/A

In the previous week, MiniMed Group had 9 more articles in the media than NovoCure. MarketBeat recorded 14 mentions for MiniMed Group and 5 mentions for NovoCure. MiniMed Group's average media sentiment score of 0.09 beat NovoCure's score of -0.01 indicating that MiniMed Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NovoCure	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MiniMed Group	1 Very Positive mention(s)	0 Positive mention(s)	13 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

MiniMed Group beats NovoCure on 9 of the 15 factors compared between the two stocks.

Get NovoCure News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NVCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NVCR vs. The Competition

Export

Metric	NovoCure	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.84B	$3.69B	$6.89B	$12.28B
Dividend Yield	N/A	2.16%	2.67%	9.39%
P/E Ratio	-10.42	20.49	27.10	23.94
Price / Sales	2.82	300.39	517.51	91.94
Price / Cash	N/A	60.31	26.68	47.25
Price / Book	5.24	7.92	10.66	6.14
Net Income	-$136.23M	$23.81M	$3.60B	$331.74M
7 Day Performance	2.51%	-1.09%	-1.23%	-1.81%
1 Month Performance	11.62%	2.56%	1.11%	-1.44%
1 Year Performance	-0.99%	42.16%	23.65%	16.33%

NovoCure Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NVCR NovoCure	2.484 of 5 stars	$15.94 +0.1%	$23.60 +48.1%	-0.5%	$1.84B	$655.35M	N/A	1,605	Upcoming Earnings
LQDA Liquidia	2.6173 of 5 stars	$71.21 -8.6%	$68.88 -3.3%	+430.1%	$6.93B	$158.32M	508.68	50
STVN Stevanato Group	2.944 of 5 stars	€19.77 0.0%	N/A	-22.9%	€5.99B	€1.34B	33.52	6,010	News Coverage Positive News
BLCO Bausch + Lomb	3.8625 of 5 stars	$16.25 +0.1%	$18.00 +10.8%	+14.9%	$5.80B	$5.10B	N/A	13,000	News Coverage
LIVN LivaNova	2.0091 of 5 stars	$82.98 +0.5%	$80.75 -2.7%	+88.7%	$4.54B	$1.39B	42.55	3,300	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NVCR) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NovoCure (NVCR) Competitors

NVCR vs. LQDA, STVN, BLCO, LIVN, and MMED

How does NovoCure compare to Liquidia?

Summary

How does NovoCure compare to Stevanato Group?

Summary

How does NovoCure compare to Bausch + Lomb?

Summary

How does NovoCure compare to LivaNova?

Summary

How does NovoCure compare to MiniMed Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NVCR vs. The Competition

NovoCure Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

NovoCure (NVCR) Competitors

NVCR vs. LQDA, STVN, BLCO, LIVN, and MMED

How does NovoCure compare to Liquidia?

Do analysts recommend LQDA or NVCR?

Does the media prefer LQDA or NVCR?

Do insiders & institutionals hold more shares of LQDA or NVCR?

Which has more risk and volatility, LQDA or NVCR?

Which has preferable earnings and valuation, LQDA or NVCR?

Is LQDA or NVCR more profitable?

Summary

How does NovoCure compare to Stevanato Group?

Which has more risk and volatility, NVCR or STVN?

Is NVCR or STVN more profitable?

Do insiders & institutionals have more ownership in NVCR or STVN?

Do analysts prefer NVCR or STVN?

Which has higher valuation and earnings, NVCR or STVN?

Does the media favor NVCR or STVN?

Summary

How does NovoCure compare to Bausch + Lomb?

Which has more volatility & risk, NVCR or BLCO?

Which has stronger valuation and earnings, NVCR or BLCO?

Do analysts rate NVCR or BLCO?

Do institutionals and insiders have more ownership in NVCR or BLCO?

Is NVCR or BLCO more profitable?

Does the media refer more to NVCR or BLCO?

Summary

How does NovoCure compare to LivaNova?

Which has more risk and volatility, LIVN or NVCR?

Is LIVN or NVCR more profitable?

Do institutionals & insiders have more ownership in LIVN or NVCR?

Do analysts rate LIVN or NVCR?

Does the media prefer LIVN or NVCR?

Which has preferable valuation and earnings, LIVN or NVCR?

Summary

How does NovoCure compare to MiniMed Group?

Which has better valuation and earnings, NVCR or MMED?

Do insiders & institutionals have more ownership in NVCR or MMED?

Do analysts prefer NVCR or MMED?

Is NVCR or MMED more profitable?

Does the media favor NVCR or MMED?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NVCR vs. The Competition

NovoCure Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools